A trial of BNT113 for head and neck cancer (AHEAD-MERIT)
This trial is comparing BT113 and pembrolizumab to pembrolizumab alone, for squamous cell head and neck cancer.
This trial is comparing BT113 and pembrolizumab to pembrolizumab alone, for squamous cell head and neck cancer.
This trial is looking at a drug called UCB4594 by itself and in combination with other treatments for solid cancers that have spread (advanced cancer).
This study is looking at the experiences of people who wear a mask during their radiotherapy for head and neck cancer.
This trial is looking at the best dose of HTL0039732 for solid tumours that have spread to another part of the body.
Head and neck cancer mortality rates are projected to rise by 12% in the UK between 2023-2025 and 2038-2040.
There could be around around 6,700 deaths of head and neck cancer every year in the UK by 2038-2040, projections suggest.
Head and neck cancer incidence rates are projected to rise by 3% in the UK between 2023-2025 and 2038-2040.
There could be around 16,300 new cases of head and neck cancer every year in the UK by 2038-2040, projections suggest.
This study is looking at new drug called alomfilimab (KY1044) by itself and in combination with atezolizumab for advanced cancers.
This study is looking at a drug called INCB106385 by itself or with another immunotherapy called retifanlimab (INCMGA00012) for some advanced solid cancers.
This trial is looking at whether a programme of exercises before treatment can help people with their eating, drinking and swallowing after treatment.
This trial is looking at adding certain targeted drugs to radiotherapy for head and neck cancer.